Mga Batayang Estadistika
| LEI | 529900OPI7B8JPXCVS70 |
| CIK | 1386570 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Niagen Bioscience, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 8, 2025 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-8 Niagen Bioscience, Inc. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Common Stock, |
|
| August 8, 2025 |
As filed with the Securities and Exchange Commission on August 8, 2025 As filed with the Securities and Exchange Commission on August 8, 2025 Registration No. |
|
| August 8, 2025 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-8 Niagen Bioscience, Inc. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Common Stock |
|
| August 8, 2025 |
As filed with the Securities and Exchange Commission on August 8, 2025 As filed with the Securities and Exchange Commission on August 8, 2025 Registration No. |
|
| August 6, 2025 |
Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook Net sales increased 37% to $31.1 million Gross margin increased 480 basis points to 65.0% Net income of $3.6 million versus breakeven in prior year period Adjusted EBITDA increased by 221% to $5.0 million Raising full year 2025 revenue outlook to 22% to 27% year-over-year growth LOS ANGELES, CA - |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 NIAGEN BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 Commission File Number: 001-37752 NIAGEN BIOSCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 26-2940963 (State or other jurisdiction of incorporation or o |
|
| August 6, 2025 |
ex992earningspresentatio Niagen Bioscience, Inc. Earnings Presentation Second Quarter 2025 Nasdaq: NAGE | August 6, 2025 SAFE HARBOR STATEMENT 2 This presentation and other written or oral statements made from time to time by representatives of Niagen Bioscience contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the |
|
| July 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2025 NIAGEN BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission F |
|
| July 29, 2025 |
Sales Agreement, dated July 25, 2025, by and between ChromaDex, Inc. and W. R. Grace & Co.-Conn. * Exhibit 10.1 Certain information in this document (indicated by [***]) has been excluded pursuant to Regulation S-K Item 601(b)(10). Such information is not material and is treated by the Registrant as private or confidential. SALES AGREEMENT THIS SALES AGREEMENT (this “Agreement”) dated as of the 1st day of April, 2025 (the “Effective Date”), by and between W. R. GRACE & CO.-CONN., a Connecticut |
|
| June 27, 2025 |
Niagen Bioscience, Inc. Employee Stock Purchase Plan Exhibit 10.2 NIAGEN BIOSCIENCE, INC. EMPLOYEE STOCK PURCHASE PLAN 1. Purpose. The purpose of the Niagen Bioscience, Inc. Employee Stock Purchase Plan (the “Plan”) is to encourage and enable Eligible Employees of Niagen Bioscience, Inc. (the “Company”) and certain Designated Subsidiaries to acquire proprietary interests in the Company through the ownership of the Company’s Common Stock purchased th |
|
| June 27, 2025 |
Niagen Bioscience, Inc. 2017 Equity Incentive Plan, as amended Exhibit 10.1 Niagen Bioscience, Inc. AMENDED 2017 Equity Incentive Plan Adopted by the Board of Directors: April 6, 2017 Approved by the Stockholders: June 20, 2017 Amended by the Board of Directors: January 21, 2018 Amended by the Board of Directors: April 24, 2018 Approved by the Stockholders June 22, 2018 Amended by the Board of Directors: April 16, 2020 Approved by the Stockholders June 19, 20 |
|
| June 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2025 NIAGEN BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission F |
|
| May 7, 2025 |
Amended and Restated Incentive Compensation Recoupment Policy Exhibit 10.9 NIAGEN BIOSCIENCE, INC. AMENDED AND RESTATED INCENTIVE COMPENSATION RECOUPMENT POLICY 1.INTRODUCTION The Board of Directors (the “Board”) of Niagen Bioscience, Inc. (the “Company”) has determined that it is in the best interests of the Company to adopt this Amended and Restated Incentive Compensation Recoupment Policy (the “A&R Policy”), which amends and restates the Company’s Incenti |
|
| May 7, 2025 |
Niagen Bioscience, Inc. 2017 Equity Incentive Plan, as amended Exhibit 10.5 Niagen Bioscience, Inc. AMENDED 2017 Equity Incentive Plan Adopted by the Board of Directors: April 6, 2017 Approved by the Stockholders: June 20, 2017 Amended by the Board of Directors: January 21, 2018 Amended by the Board of Directors: April 24, 2018 Approved by the Stockholders June 22, 2018 Amended by the Board of Directors: April 16, 2020 Approved by the Stockholders June 19, 20 |
|
| May 7, 2025 |
Amended and Restated Non-Employee Director Compensation Policy Exhibit 10.8 NIAGEN BIOSCIENCE, INC. Amended and Restated Non-Employee Director Compensation Policy Adopted: November 8, 2016 Amended and Restated: November 16, 2016 Amended and Restated: April 6, 2017 Amended and Restated: June 22, 2018 Amended: March 3, 2025 Effective Date: July 3, 2016 Each member of the Board of Directors (the “Board”) who is a member as of November 8, 2016 or thereafter and w |
|
| May 7, 2025 |
Form of Stock Option Agreement under Niagen Bioscience, Inc. 2017 Equity Incentive Plan, as amended Exhibit 10.6 Niagen Bioscience, Inc. 2017 Equity Incentive Plan Option Agreement (Incentive Stock Option or Nonstatutory Stock Option) Pursuant to the accompanying Option Grant Notice (the “Grant Notice”) and this Option Agreement (the “Agreement”), Niagen Bioscience, Inc. (the “Company”) has granted you an Option under the Niagen Bioscience, Inc. 2017 Equity Incentive Plan (the “Plan”) to purchas |
|
| May 7, 2025 |
ex992earningspresentatio Niagen Bioscience, Inc. Earnings Presentation First Quarter 2025 Nasdaq: NAGE | May 7, 2025 SAFE HARBOR STATEMENT 2 This presentation and other written or oral statements made from time to time by representatives of Niagen Bioscience contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Secu |
|
| May 7, 2025 |
Exhibit 10.4 SEVENTH MODIFICATION TO BUSINESS FINANCING AGREEMENT This Seventh Modification to Business Financing Agreement (this “Amendment”) is entered into as of March 24, 2025, by and among WESTERN ALLIANCE BANK, an Arizona corporation (“Lender”), NIAGEN BIOSCIENCE, INC., a Delaware corporation (formerly known as CHROMADEX CORPORATION, a Delaware corporation), CHROMADEX, INC., a California cor |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 NIAGEN BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 7, 2025 |
Form of Stock Certificate representing shares of the Registrant’s Common Stock formofstockcertificateni THIS CERTIFIES THAT is the owner of CUSIP DATED COUNTERSIGNED AND REGISTERED: COMPUTERSHARE TRUST COMPANY, N. |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 Commission File Number: 001-37752 NIAGEN BIOSCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 26-2940963 (State or other jurisdiction of incorporation or |
|
| May 7, 2025 |
Exhibit 10.7 Niagen Bioscience, Inc. 2017 Equity Incentive Plan Restricted Stock Unit Award Agreement Pursuant to the accompanying Restricted Stock Unit Award Grant Notice (the “Grant Notice”) and this Restricted Stock Unit Award Agreement (the “Agreement”), Niagen Bioscience, Inc. (the “Company”) has granted you a Restricted Stock Unit Award (the “Award”) under the Niagen Bioscience, Inc. 2017 Eq |
|
| May 7, 2025 |
Exhibit 10.3 SECOND AMENDMENT TO LEASE This Second Amendment to Lease (this “Second Amendment”) is made as of March 11, 2025, by and between 62 1625-1751 S. FORDHAM LLC, a Colorado limited liability company and 64 1625-1751 S. FORDHAM LLC, a Colorado limited liability company (as tenantsin-common, collectively the “Landlord”) and CHROMADEX ANALYTICS, INC., a Nevada corporation (hereinafter referre |
|
| May 7, 2025 |
Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook Total net sales of $30.5 million, up $8.3 million or 38% year-over-year, gross margin of 63.4%, net income of $5.1 million and Adjusted EBITDA of $4.9 million for the three months ended March 31, 2025 and increased full year 2025 outlook. LOS ANGELES, CA - May 7, 2025 - Niagen Bioscience, Inc. (NASDAQ:NAGE) |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Defin |
|
| March 19, 2025 |
Amended and Restated Bylaws of Niagen Bioscience, Inc. Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF NIAGEN BIOSCIENCE, INC. (hereinafter called the “Corporation”) ARTICLE I. OFFICES Section 1. Registered Office. The registered office of the Corporation in the State of Delaware shall be in the Corporation Trust Center, 1209 Orange Street, in the City of Wilmington, County of New Castle, Delaware, 19801 and the name of the registered agent of the Corporat |
|
| March 19, 2025 |
Exhibit 99.1 ChromaDex Evolves into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ with Precision Science The rebrand celebrates the company’s clinically proven flagship patented nicotinamide riboside (NR) ingredient, Niagen, the most well-researched, efficient, high-quality, and legal NAD+ booster available [Caption: Niagen Bioscience’s state-of-the-art research and deve |
|
| March 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2025 NIAGEN BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission |
|
| March 19, 2025 |
Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation niagenbioscienceinc-deam Delaware The First State Page 1 4564086 8100 Authentication: 203188858 SR# 20251087401 Date: 03-17-25 You may verify this certificate online at corp. |
|
| March 4, 2025 |
Subsidiaries of ChromaDex Corporation EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT (As of December 31, 2024) Entity Name President Company / Owner Jurisdiction of Formation ChromaDex, Inc. ChromaDex Corporation California ChromaDex International, Inc. ChromaDex Corporation Cayman Islands ChromaDex Analytics, Inc. ChromaDex, Inc. Nevada ChromaDex Europa B.V. ChromaDex, Inc. Netherlands Chromadex Sağlık Ürünleri Anonim Şirketia ChromaDex |
|
| March 4, 2025 |
ex992-cdxcearningspresen ChromaDex Earnings Conference Call Fourth Quarter 2024 Nasdaq: CDXC | March 4, 2025 2 SAFE HARBOR STATEMENT This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. |
|
| March 4, 2025 |
EXHIBIT 10.38 SIXTH MODIFICATION TO BUSINESS FINANCING AGREEMENT This Sixth Modification to Business Financing Agreement (this “Amendment”) is entered into as of November 18, 2024, by and among WESTERN ALLIANCE BANK, an Arizona corporation (“Lender”), CHROMADEX CORPORATION, a Delaware corporation, CHROMADEX, INC., a California corporation, and CHROMADEX ANALYTICS, INC., a Nevada corporation (indiv |
|
| March 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2025 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 4, 2025 |
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results EXHIBIT 99.1 ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results Full year net sales of $99.6 million, up 19% from the prior year, gross margin of 61.8%, net income of $8.6 million, Adjusted EBITDA of $8.5 million, and $12.1 million in operating cash flows. Ended the year with $44.7 million in cash and no debt. Fourth quarter net sales of $29.1 million, up 37% from the prior |
|
| March 4, 2025 |
EXHIBIT 19.1 CHROMADEX Date Issued: 3/4/2025 Page #: 1 of 7 Policy INSIDER TRADING COMPLIANCE Approved By: Board of Directors Department: Legal Applies To: Worldwide Operations Statement of Purpose ChromaDex Corporation (the “Company”) has adopted this Insider Trading Policy (the “Policy”) in order to take an active role in the prevention of insider trading violations by officers, directors, emplo |
|
| March 4, 2025 |
Offer Letter, dated June 27, 2024, by and between Carlos Lopez and ChromaDex, Inc. EXHIBIT 10.58 June 27, 2024 CONFIDENTIAL Carlos Lopez ** RE: Offer of Employment as Senior Vice President, General Counsel for ChromaDex, Inc. Dear Carlos Lopez, We are pleased to extend you an offer of full-time employment for the position of Senior Vice President, General Counsel. ChromaDex, Inc. (“ChromaDex”), a subsidiary of ChromaDex, Corp., whose corporate headquarters is located at 10900 Wi |
|
| March 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission file number 001-37752 CHROMADEX CORPORATION ( |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2025 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission |
|
| February 27, 2025 |
EXHIBIT 10.1 AMENDMENT TO EMPLOYMENT AGREEMENT THIS AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is dated as of February 25, 2025 (the “Amendment Effective Date”), by and among ChromaDex Corporation., a Delaware corporation (the “Company”), and Robert Fried, the undersigned individual (“Executive” and, together with the Company, the “Parties”), is intended to modify the Amended and Restate |
|
| February 27, 2025 |
Exhibit 10.2 ChromaDex Corporation Performance Stock Unit Award Grant Notice (2017 Equity Incentive Plan) ChromaDex Corporation (the “Company”), pursuant to its 2017 Equity Incentive Plan (as amended from time-to-time, the “Plan”), hereby awards to Participant a performance stock unit award that grants Participant the right to receive the number of shares of Common Stock specified below (“Performa |
|
| December 16, 2024 |
Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2024 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission |
|
| December 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2024 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission |
|
| November 21, 2024 |
ChromaDex Corporation $47,800,000 Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-272828 PROSPECTUS SUPPLEMENT To Prospectus Supplement dated July 5, 2023 (To Prospectus dated July 5, 2023) ChromaDex Corporation $47,800,000 Common Stock This supplement (this “Supplement”) supplements the prospectus supplement, dated July 5, 2023 (the “Prospectus Supplement”), relating to the sale of shares of our common stock, $0.001 par val |
|
| November 21, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2024 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission |
|
| November 21, 2024 |
CHROMADEX CORPORATION AMENDMENT NO. 1 TO AT MARKET ISSUANCE SALES AGREEMENT November 20, 2024 Raymond James & Associates, Inc. 277 Park Avenue, Suite 410 New York, New York 10172 Attention: Stuart Barich and Tom Donegan Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, California 92660 Attention: Paul Zaffaroni and Jonathan Alyn Ladies and Gentlemen: This Amendment No. 1 |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 Commission File Number: 001-37752 CHROMADEX CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 26-2940963 (State or other jurisdiction of incorporation o |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2024 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission |
|
| October 31, 2024 |
ChromaDex Earnings Presentation Third Quarter 2024 Rob Fried Chief Executive Officer Ozan Pamir Chief Financial Officer Andrew Shao SVP Scientific & Regulatory Affairs Nasdaq: CDXC | October 31, 2024 SAFE HARBOR STATEMENT SAFE HARBOR STATEMENT 2 This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. |
|
| October 31, 2024 |
Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY […***…], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. TENTH AMENDMENT Manufacturing and Supply Agreement between W. R. Grace & Co.-Conn. and ChromaDex, Inc. This Tenth Amendment (the “Tenth Amendment") to that certain Manufacturing and Supply Ag |
|
| October 31, 2024 |
ChromaDex Corporation Reports Third Quarter 2024 Financial Results Total net sales of $25. |
|
| October 11, 2024 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2024 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission F |
|
| September 20, 2024 |
ChromaDex Appoints Ozan Pamir as Chief Financial Officer EXHIBIT 99.1 ChromaDex Appoints Ozan Pamir as Chief Financial Officer LOS ANGELES – Friday, September 20, 2024 – ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announces the appointment of Ozan Pamir as Chief Financial Officer. Mr. Pamir will oversee all ChromaDex corporate finance matters, including accountin |
|
| September 20, 2024 |
Offer Letter, dated September 10, 2024, by and between Ozan Pamir and ChromaDex, Inc. 10900 Wilshire Blvd, Suite 600 | Westwood, CA 90024 USA | T: +1 310-388-6706 | www. |
|
| September 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2024 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commissio |
|
| August 21, 2024 |
EX-99.1 2 d863039dex991.htm EX-99.1 CUSIP No. 171077407 SC 13D/A Page 23 of 24 Exhibit 99.1 Joint Filing Agreement The persons or entities named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Shares of the Issuer and further agree that this joint filing agreement be included as an exhibit to this Schedule |
|
| August 21, 2024 |
CDXC / ChromaDex Corporation / Prime Tech Global Ltd - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) INFORMATION INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 9)* CHROMADEX CORPORATION (Name of Issuer) COMMON STOCK, $0,001 PAR VALUE PER SHARE (Title of Class of Securities) 171077407 (CUSIP Number) Li Ka Shing Attention: Pau |
|
| August 21, 2024 |
EX-99.11 Exhibit 99.11 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made on 20 August, 2024 BY AND AMONG: (1) Prime Tech Global Limited, a British Virgin Islands company (“Prime Tech”); (2) Alpha Mount International Limited, a British Virgin Islands company (“Alpha Mount” and together with Prime Tech, the “Sellers”); (3) Brilliant Dynasty Limited, a Britis |
|
| August 21, 2024 |
CDXC / ChromaDex Corporation / Pioneer Step Holdings Ltd - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) INFORMATION INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 15)* CHROMADEX CORPORATION (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 171077407 (CUSIP Number) Pioneer Step Holdings Lim |
|
| August 21, 2024 |
EX-99.16 3 d863039dex9916.htm EX-99.16 Exhibit 99.16 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made on 20 August, 2024 BY AND AMONG: (1) Prime Tech Global Limited, a British Virgin Islands company (“Prime Tech”); (2) Alpha Mount International Limited, a British Virgin Islands company (“Alpha Mount” and together with Prime Tech, the “Sellers”); (3) Brill |
|
| August 21, 2024 |
EX-99.1 Exhibit 99.1 Joint Filing Agreement The persons or entities named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Shares of the Issuer and further agree that this joint filing agreement be included as an exhibit to this Schedule 13D. In evidence thereof, the undersigned, being duly authorized, have |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 Commission File Number: 001-37752 CHROMADEX CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 26-2940963 (State or other jurisdiction of incorporation or org |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 7, 2024 |
ChromaDex Corporation Reports Second Quarter 2024 Financial Results Total net sales of $22. |
|
| August 7, 2024 |
ChromaDex Earnings Presentation Second Quarter 2024 Rob Fried Chief Executive Officer James Lee Interim Chief Financial Officer Andrew Shao SVP Scientific & Regulatory Affairs Nasdaq: CDXC | August 7, 2024 SAFE HARBOR STATEMENT SAFE HARBOR STATEMENT 2 This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. |
|
| July 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2024 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2024 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 25, 2024 |
EXHIBIT 10.1 June 25, 2024 VIA ELECTRONIC MAIL ONLY Brianna Gerber [email protected] Dear Brianna: You have notified us that you are resigning your employment at ChromaDex Corporation (the “Company”), including officer and board roles at all of its subsidiaries, effective at the close of business on July 12, 2024 (the “Separation Date”). We wish you well in your future endeavors. You hereby con |
|
| June 24, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2024 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Commission File Number: 001-37752 CHROMADEX CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 26-2940963 (State or other jurisdiction of incorporation or or |
|
| May 8, 2024 |
ex992-investorpresentati ChromaDex Earnings Conference Call First Quarter 2024 Rob Fried Chief Executive Officer Brianna Gerber Chief Financial Officer Andrew Shao SVP Scientific & Regulatory Affairs Nasdaq: CDXC | May 8, 2024 SAFE HARBOR STATEMENT SAFE HARBOR STATEMENT 2 This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission File |
|
| May 8, 2024 |
ChromaDex Corporation Reports First Quarter 2024 Financial Results ChromaDex Corporation Reports First Quarter 2024 Financial Results Total net sales of $22. |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Defin |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2024 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 6, 2024 |
Amended and Restated Incentive Compensation Recoupment Policy Exhibit 10.60 CHROMADEX CORPORATION AMENDED AND RESTATED INCENTIVE COMPENSATION RECOUPMENT POLICY 1.INTRODUCTION The Board of Directors (the “Board”) of ChromaDex Corporation (the “Company”) has determined that it is in the best interests of the Company to adopt this Amended and Restated Incentive Compensation Recoupment Policy (the “A&R Policy”), which amends and restates the Company’s Incentive |
|
| March 6, 2024 |
Exhibit 10.24 FOURTH AMENDMENT TO LEASE This FOURTH AMENDMENT TO LEASE (this "Fourth Amendment") is made and entered into as of December 20, 2018, by and between 10900 WILSHIRE, L.L.C., a Delaware limited liability company ("Landlord"), and CHROMADEX, INC., a California corporation ("Tenant"). RECITALS: A. Landlord and Tenant are parties to that certain Leaser dated July 6, 2017 (the "Office Lease |
|
| March 6, 2024 |
ChromaDex Earnings Conference Call Fourth Quarter 2023 Rob Fried Chief Executive Officer Brianna Gerber Chief Financial Officer Andrew Shao SVP Scientific & Regulatory Affairs Nasdaq: CDXC | March 6, 2024 2 SAFE HARBOR STATEMENT This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission file number 001-37752 CHROMADEX CORPORATION ( |
|
| March 6, 2024 |
Subsidiaries of ChromaDex Corporation EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT (As of December 31, 2023) Entity Name President Company / Owner Jurisdiction of Formation ChromaDex, Inc. ChromaDex Corporation California ChromaDex International, Inc. ChromaDex Corporation Cayman Islands ChromaDex Analytics, Inc. ChromaDex, Inc. Nevada ChromaDex Europa B.V. ChromaDex, Inc. Netherlands Chromadex Sağlık Ürünleri Anonim Şirketia ChromaDex |
|
| March 6, 2024 |
EXHIBIT 99.1 ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results Fourth quarter net sales of $21.2 million, gross margin of 61.0%, and net income of $0.1 million. Full year net sales of $83.6 million, up 16% from the prior year, gross margin of 60.8%, net loss of only $4.9 million, positive Adjusted EBITDA of $1.9 million and positive operating cash flows. LOS ANGELES, CA - M |
|
| March 6, 2024 |
Exhibit 97.1 CHROMADEX CORPORATION Dodd-Frank Clawback Policy The Board of Directors (the “Board”) of ChromaDex Corporation (the “Company”) believes that it is in the best interests of the Company and its shareholders to adopt this Dodd-Frank Clawback Policy (this “Policy”), which provides for the recovery of certain incentive compensation in the event of an Accounting Restatement (as defined belo |
|
| December 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2023 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission |
|
| December 13, 2023 |
EXHIBIT 10.2 FIFTH MODIFICATION TO BUSINESS FINANCING AGREEMENT This Fifth Modification to Business Financing Agreement (this “Amendment”) is entered into as of December 8, 2023, by and among WESTERN ALLIANCE BANK, an Arizona corporation (“Lender”), CHROMADEX CORPORATION, a Delaware corporation, CHROMADEX, INC., a California corporation, and CHROMADEX ANALYTICS, INC., a Nevada corporation (individ |
|
| December 13, 2023 |
EXHIBIT 10.1 FOURTH MODIFICATION TO BUSINESS FINANCING AGREEMENT This Fourth Modification to Business Financing Agreement (this “Amendment”) is entered into as of November 9, 2023, by and among WESTERN ALLIANCE BANK, an Arizona corporation (“Lender”), CHROMADEX CORPORATION, a Delaware corporation, CHROMADEX, INC., a California corporation, and CHROMADEX ANALYTICS, INC., a Nevada corporation (indiv |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 Commission File Number: 001-37752 CHROMADEX CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 26-2940963 (State or other jurisdiction of incorporation o |
|
| November 8, 2023 |
Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY […***…], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. NINTH AMENDMENT Manufacturing and Supply Agreement between W. R. Grace & Co.-Conn. and ChromaDex, Inc. This Ninth Amendment (the “Ninth Amendment") to that certain Manufacturing and Supply Ag |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission |
|
| November 8, 2023 |
Exhibit 10.1 SIXTH AMENDMENT TO LEASE This SIXTH AMENDMENT TO LEASE (this "Sixth Amendment") is made and entered into as of October 11, 2023, by and between 10900 WILSHIRE, L.L.C., a Delaware limited liability company ("Landlord"), and CHROMADEX, INC., a California corporation ("Tenant"). R E C I T A L S : A.Landlord and Tenant are parties to that certain Lease, dated July 6, 2017 (the "Original L |
|
| November 8, 2023 |
ChromaDex Earnings Conference Call Third Quarter 2023 Rob Fried Chief Executive Officer Brianna Gerber Chief Financial Officer Andrew Shao SVP Scientific & Regulatory Affairs Nasdaq: CDXC | November 8, 2023 SAFE HARBOR STATEMENT SAFE HARBOR STATEMENT 2 This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. |
|
| November 8, 2023 |
Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. FIRST AMENDMENT TO AMENDED AND RESTATED SUPPLY AGREEMENT This First Amendment to Amended and Restated Supply Agreement (the “First Amendment”) is entered into this August 16, 2023 |
|
| November 8, 2023 |
ChromaDex Corporation Reports Third Quarter 2023 Financial Results Total net sales of $19. |
|
| September 7, 2023 |
EX-99.1 Exhibit 99.1 Joint Filing Agreement The persons or entities named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Shares of the Issuer and further agree that this joint filing agreement be included as an exhibit to this Schedule 13D. In evidence thereof, the undersigned, being duly authorized, have |
|
| September 7, 2023 |
CDXC / Chromadex Corp / Champion River Ventures Ltd - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHlNGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) INFORMATION INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 8)* CHROMADEX CORPORATION (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 171077407 (CUSIP Number) Champion River Ventures Li |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 9, 2023 |
ex992-earningspresentati ChromaDex Earnings Conference Call Second Quarter 2023 Rob Fried Chief Executive Officer Brianna Gerber Chief Financial Officer Andrew Shao SVP Scientific & Regulatory Affairs Nasdaq: CDXC | August 9, 2023 SAFE HARBOR STATEMENT SAFE HARBOR STATEMENT 2 This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. |
|
| August 9, 2023 |
ChromaDex Corporation Reports Second Quarter 2023 Financial Results Strong quarter with total net sales of $20. |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 Commission File Number: 001-37752 CHROMADEX CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 26-2940963 (State or other jurisdiction of incorporation or org |
|
| July 6, 2023 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-272828 PROSPECTUS SUPPLEMENT (To Prospectus dated July 5, 2023) $47,800,000 Common Stock We have entered into an At Market Issuance Sales Agreement (the “Sales Agreement”), dated as of June 12, 2020, with B. Riley Securities, Inc. (“B. Riley Securities”) and Raymond James & Associates, Inc. (“Raymond James” and together with B. Riley Securities |
|
| June 30, 2023 |
CHROMADEX CORPORATION 10900 Wilshire Blvd. Suite 600 Los Angeles, CA 90024 CHROMADEX CORPORATION 10900 Wilshire Blvd. Suite 600 Los Angeles, CA 90024 June 30, 2023 VIA EDGAR Jason Drory United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-7010 Re: ChromaDex Corporation Registration Statement on Form S-3 (File No. 333-272828) Dear Mr. Drory: Pursuant to Rule 461 of the Securities Act of 1933, as amended |
|
| June 22, 2023 |
Exhibit 107 Calculation of Fee Filing Tables Form S-3 (Form Type) ChromaDex Corporation (Exact name of Registrant as Specified in its Charter) Table 1 – Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid Equity Common Stock, par value $0. |
|
| June 22, 2023 |
As filed with the United States Securities and Exchange Commission on June 22, 2023 As filed with the United States Securities and Exchange Commission on June 22, 2023 Registration No. |
|
| June 22, 2023 |
Form of Indenture, by and between the Registrant and one or more trustees to be named. Exhibit 4.4 CHROMADEX CORPORATION, Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 20 Debt Securities Table of Contents Page Article 1 DEFINITIONS 1 Section 01. Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 01. Designation and Terms of Securities 5 Section 02. Form of Securities and Trustee’s Certificate 8 Section |
|
| June 22, 2023 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) ChromaDex Corporation (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) (2) Proposed Maximum Offering Price Per Unit(3) Maximum Aggregate Offering Price(3) Fee Rate Amount of Registration Fee(3) Equity Common Stock, par value $0. |
|
| June 22, 2023 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.8 ChromaDex Corporation and , As Warrant Agent Form of Debt Securities Warrant Agreement Dated As Of ChromaDex Corporation Form of Debt Securities Warrant Agreement This Debt Securities Warrant Agreement (this “Agreement”), dated as of [●], between ChromaDex Corporation, a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing |
|
| June 22, 2023 |
Form of Common Stock Warrant Agreement and Warrant Certificate. Exhibit 4.7 ChromaDex Corporation and , As Warrant Agent Form of Common Stock Warrant Agreement Dated As Of ChromaDex Corporation Form of Common Stock Warrant Agreement This Common Stock Warrant Agreement (this “Agreement”), dated as of [●], between ChromaDex Corporation, a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under th |
|
| June 22, 2023 |
As filed with the Securities and Exchange Commission on June 22, 2023 As filed with the Securities and Exchange Commission on June 22, 2023 Registration No. |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 20, 2023 |
ChromaDex Corporation 2017 Equity Incentive Plan, as amended Exhibit 10.1 ChromaDex Corporation AMENDED 2017 Equity Incentive Plan Adopted by the Board of Directors: April 6, 2017 Approved by the Stockholders: June 20, 2017 Amended by the Board of Directors: January 21, 2018 Amended by the Board of Directors: April 24, 2018 Approved by the Stockholders June 22, 2018 Amended by the Board of Directors: April 16, 2020 Approved by the Stockholders June 19, 2020 |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission File |
|
| May 10, 2023 |
ChromaDex Corporation Reports First Quarter 2023 Financial Results Record net sales of $22. |
|
| May 10, 2023 |
ChromaDex Earnings Conference Call First Quarter 2023 Rob Fried Chief Executive Officer Brianna Gerber Chief Financial Officer Andrew Shao SVP Scientific & Regulatory Affairs Nasdaq: CDXC | May 10, 2023 SAFE HARBOR STATEMENT SAFE HARBOR STATEMENT 2 This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 Commission File Number: 001-37752 CHROMADEX CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 26-2940963 (State or other jurisdiction of incorporation or or |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Defin |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a party other than the Registrant ☐ Check the appropriate box: ☑ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2023 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 17, 2023 |
Amended and Restated Bylaws of the Registrant EXHIBIT 3.1 AMENDED AND RESTATED BYLAWS OF CHROMADEX CORPORATION (hereinafter called the “Corporation”) ARTICLE I. OFFICES Section 1.Registered Office. The registered office of the Corporation in the State of Delaware shall be in the Corporation Trust Center, 1209 Orange Street, in the City of Wilmington, County of New Castle, Delaware, 19801 and the name of the registered agent of the Corporation |
|
| March 8, 2023 |
EXHIBIT 10.6 WAIVER OF 2022 BONUS COMPENSATION I, Frank L. Jaksch, Jr., hereby affirm and state that on June 3, 2022, I notified ChromaDex Corporation (the “Company”) that I intended to resign from my capacity as Executive Director and an employee of the Company, and as an officer, employee, and director of any subsidiaries of the Company. I continue to serve on the board of directors (the “Board” |
|
| March 8, 2023 |
cdxcearningspresentation ChromaDex Earnings Conference Call Fourth Quarter 2022 Rob Fried Chief Executive Officer Brianna Gerber Chief Financial Officer Andrew Shao SVP Scientific & Regulatory Affairs Nasdaq: CDXC | March 8, 2023 2 SAFE HARBOR STATEMENT This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. |
|
| March 8, 2023 |
EXHIBIT 99.1 ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2022 Results Record revenue in Q4 2022 with $21.0 million in total net sales, up 18% from the prior year quarter, a net loss of $1.4 million and an Adjusted EBITDA profit of $0.4 million. Full year total net sales of $72.0 million with $60.1 million from Tru Niagen. LOS ANGELES, CA - March 8, 2023 - ChromaDex Corp. (NASDAQ:C |
|
| March 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission file number 001-37752 CHROMADEX CORPORATION ( |
|
| March 8, 2023 |
Subsidiaries of ChromaDex Corporation EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT (As of December 31, 2022) Entity Name President Company / Owner Jurisdiction of Formation ChromaDex, Inc. ChromaDex Corporation California ChromaDex International, Inc. ChromaDex Corporation Cayman Islands ChromaDex Analytics, Inc. ChromaDex, Inc. Nevada ChromaDex Europa B.V. ChromaDex, Inc. Netherlands Chromadex Sağlık Ürünleri Anonim Şirketia ChromaDex |
|
| March 8, 2023 |
EXHIBIT 10.50 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY […***…], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. EIGHTH AMENDMENT Manufacturing and Supply Agreement between W. R Grace & Co. and ChromaDex, Inc. This Eighth Amendment to the Manufacturing and Supply Agreement (the "Eighth Amendment") is m |
|
| March 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2023 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission Fil |
|
| January 5, 2023 |
ChromaDex Named Brianna Gerber Chief Financial Officer LOS ANGELES ? January 5, 2023 ? ChromaDex Corp. |
|
| January 5, 2023 |
EX-10.1 2 gerberbriannaexecutiveem.htm EX-10.1 CHROMADEX CORPORATION EXECUTIVE EMPLOYMENT AGREEMENT for Brianna Gerber This Executive Employment Agreement (this “Agreement”) is entered into as of January 1, 2023 (the “Effective Date”), by and between Brianna Gerber (“Executive”) and ChromaDex Corporation, a Delaware corporation (the “Company”). This Agreement supersedes and replaces all prior offe |
|
| January 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2023 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission F |
|
| November 17, 2022 |
2,480,000 Shares Common Stock Offered by the Selling Stockholders Filed pursuant to Rule 424(b)(3) Registration No. 333-268148 PROSPECTUS 2,480,000 Shares Common Stock Offered by the Selling Stockholders This prospectus relates to the offer and resale by certain selling stockholders from time to time of up to 2,480,000 shares of our common stock, par value $0.001 per share (?Common Stock?). The selling stockholders may sell the shares of Common Stock described i |
|
| November 14, 2022 |
CHROMADEX CORPORATION 10900 Wilshire Blvd. Suite 600 Los Angeles, CA 90024 CHROMADEX CORPORATION 10900 Wilshire Blvd. Suite 600 Los Angeles, CA 90024 November 14, 2022 VIA EDGAR Lauren Hamill United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-7010 Re: ChromaDex Corporation Registration Statement on Form S-3 (File No. 333-268148) Dear Ms. Hamill: Pursuant to Rule 461 of the Securities Act of 1933, as |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ChromaDex Corporation (Exact Name of Registrant As Specified in Its Charter) Delaware 26-2940963 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification Number) 10900 Wilshire Blvd., Suite 600 Los Angeles, California 90024 ( |
|
| November 3, 2022 |
Calculation of Filing Fee Tables Form S-3 ChromaDex Corporation (Exact names of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Share(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0. |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2022 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission |
|
| November 2, 2022 |
cdxcearningspresentation ChromaDex Earnings Conference Call Third Quarter 2022 Rob Fried Chief Executive Officer Brianna Gerber SVP, Finance / Interim Chief Financial Officer Nasdaq: CDXC | November 2022 SAFE HARBOR STATEMENT This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 Commission File Number: 001-37752 CHROMADEX CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 26-2940963 (State or other jurisdiction of incorporation o |
|
| November 2, 2022 |
cdxc-amendedandrestateds 276544406 v1 1 of 42 NHSc’s and ChromaDex’s Initials CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| November 2, 2022 |
ChromaDex Corporation Reports Third Quarter 2022 Financial Results Total net sales of $17. |
|
| October 19, 2022 |
EXHIBIT I JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. |
|
| October 19, 2022 |
CDXC / Chromadex Corp / Societe des Produits Nestle S.A. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 CHROMADEX CORPORATION (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 171077407 (CUSIP Number) Nestl? S.A. Avenue Nestl?, 55 1800 Vevey Switzerland Attention: General Counsel Facsimile: 011-41-21-924-2821 with a copy to: David A. Carpenter, E |
|
| October 11, 2022 |
Exhibit 99.1 ChromaDex and Nestl? Health Science Announce New Niagen? Commercial Supply Agreement and $5 Million Investment ? The new agreement extends non-exclusive rights to sell Niagen? in multi-ingredient dietary supplements ? The agreement includes an initial Niagen? ingredient purchase commitment of $1.975 million in 2022 ? ChromaDex will be eligible to receive commercial milestone payments, |
|
| October 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 10, 2022 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission |
|
| October 11, 2022 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of October 10, 2022, between ChromaDex Corporation, a Delaware corporation (the ?Company?), and Soci?t? des Produits Nestl? SA, a soci?t? anonyme organized under the laws of Switzerland (the ?Purchaser?). WHEREAS, the Company and the Purchaser are parties to that certain supply agreement da |
|
| October 11, 2022 |
Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-239144 PROSPECTUS SUPPLEMENT (To Prospectus Dated June 26, 2020) 3,816,794 Shares Common Stock We are offering to an institutional investor 3,816,794 shares of our common stock at a price of $1.31 per share pursuant to this prospectus supplement and the accompanying prospectus. Our common stock is traded on the Nasdaq Capital Market u |
|
| October 3, 2022 |
CDXC / Chromadex Corp / Pioneer Step Holdings Ltd - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHlNGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) INFORMATION INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 14)* CHROMADEX CORPORATION (Name of lssuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 171077407 (CUSIP Number) Pioneer Step Holdings Limited Dvor |
|
| October 3, 2022 |
Good-Bye! (Leaving the SEC Website) This page is temporarily unavailable. Exhibit 99.1 Joint Filing Agreement The persons or entities named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Shares of the Issuer and further agree that this joint filing agreement be included as an exhibit to this Schedule 13D. In evidence thereof, the undersigned, being duly authorized, have executed |
|
| October 3, 2022 |
Exhibit 10.1 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SHAREHOLDERS AGREEMENT among HONG KONG TAIKUK (CHINA) GROUP LTD. ASIA PACIFIC SCIENTIFIC, INC. and CHROMADEX ASIA PACIFIC VENTURES LIMITED DATED: SEP |
|
| October 3, 2022 |
CDXC / Chromadex Corp / Champion River Ventures Ltd - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) INFORMATION INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 7)* CHROMADEX CORPORATION (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 171077407 (CUSIP Number) Champion River Ventures Limited Att |
|
| October 3, 2022 |
Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (the ?Agreement?) is made as of September 30, 2022, by and among ChromaDex Corporation, a corporation organized and existing under the laws of the State of Delaware (the ?Company?), and each purchaser signatory hereto (each, a ?Purchaser? and collectively to the extent there is more than one Purchaser, the ?Purchasers?). |
|
| October 3, 2022 |
Exhibit 10.4 TERMINATION AGREEMENT THIS TERMINATION AGREEMENT (this ?Agreement?) is entered into on September 30, 2022 (the ?Effective Date?) by and among ChromaDex Corporation, a Delaware corporation (?CDXC?), Crystal Lake Developments Limited, a company incorporated under the laws of the British Virgin Islands (?Crystal Lake?), Pioneer Idea Holdings Limited, a company organized under the laws of |
|
| October 3, 2022 |
Securities Purchase Agreement, dated September 30, 2022, by and among the Company and the Purchasers Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of September 30, 2022, by and among ChromaDex Corporation, a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively to the extent there is more than one Purchaser, the ?Pur |
|
| October 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 30, 2022 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commissio |
|
| October 3, 2022 |
Exhibit 99.1 Joint Filing Agreement The persons or entities named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Shares of the Issuer and further agree that this joint filing agreement be included as an exhibit to this Schedule 13D. In evidence thereof, the undersigned, being duly authorized, have executed |
|
| August 10, 2022 |
Exhibit 99.2 |
|
| August 10, 2022 |
Exhibit 10.1 August 10, 2022 VIA ELECTRONIC MAIL ONLY Kevin Farr [email protected] Dear Kevin: Please be advised that the Company is terminating your employment without Cause, as that term is defined in your Executive Employment Agreement dated October 5, 2017 (the ?EEA?). The ?Termination Date? for the purposes of this Agreement will be August 12, 2022. The separation benefits contemplated by |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 Commission File Number: 001-37752 CHROMADEX CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 26-2940963 (State or other jurisdiction of incorporation or org |
|
| August 10, 2022 |
Consultant Agreement, dated August 10, 2022, by and between the Company and Kevin Farr Exhibit 10.2 CONSULTANT AGREEMENT This Consultant Agreement (the ?Agreement?) is entered into this August 13, 2022 (?Effective Date?) by and between ChromaDex, Inc., having its principal offices located 10900 Wilshire Blvd., Suite 600, Los Angeles, California 90024, U.S.A. (?ChromaDex?), and Kevin M. Farr, with an address of 412 Via Almar, Palos Verdes Estates, California 90274, U.S.A. (?Consultan |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 10, 2022 |
Exhibit 99.1 ChromaDex Corporation Reports Second Quarter 2022 Financial Results Total net sales of $16.7 million for the three months ended June 30, 2022 with $14.5 million from Tru Niagen® and gross margin of 60.0% for the quarter. LOS ANGELES, CA - August 10, 2022 - ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the second quarter of 2022. Second Quarter 2022 and Recent Hig |
|
| June 21, 2022 |
Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2022 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2022 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission File |
|
| May 20, 2022 |
CDXC / Chromadex Corp / Pioneer Step Holdings Ltd - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) INFORMATION INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 13)* CHROMADEX CORPORATION (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 171077407 (CUSIP Number) Pioneer Step Holdings Limited Dvor |
|
| May 20, 2022 |
CDXC / Chromadex Corp / SHING LI KA - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) INFORMATION INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 6)* CHROMADEX CORPORATION (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 171077407 (CUSIP Number) Champion River Ventures Limited Att |
|
| May 20, 2022 |
EX-99.1 Exhibit 99.1 Joint Filing Agreement The persons or entities named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Shares of the Issuer and further agree that this joint filing agreement be included as an exhibit to this Schedule 13D. In evidence thereof, the undersigned, being duly authorized, have |
|
| May 20, 2022 |
Exhibit 99.1 Joint Filing Agreement The persons or entities named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Shares of the Issuer and further agree that this joint filing agreement be included as an exhibit to this Schedule 13D. In evidence thereof, the undersigned, being duly authorized, have executed |
|
| May 19, 2022 |
Exhibit 10.1 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. JOINT VENTURE AGREEMENT THIS JOINT VENTURE AGREEMENT (this ?Agreement?) is made as of May 19, 2022 (the ?Effective Date?) between Crystal Lake Develo |
|
| May 19, 2022 |
Exhibit 99.1 ChromaDex Announces Agreement to Launch Commercial Joint Venture in Mainland China The signed agreement establishes beachhead to broadly market and distribute Tru Niagen? to Mainland China?s aging population LOS ANGELES, CA - May 19, 2022 - ChromaDex Corp. (NASDAQ:CDXC) (?the Company?) a global bioscience company dedicated to healthy aging, today announced it has entered into an agree |
|
| May 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2022 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission File |
|
| May 12, 2022 |
Exhibit 10.7 ChromaDex Corporation July 8, 2021 Lisa Hatton Harrington Newport Coast, CA 92657 Re: Transition and Separation Agreement Dear Lisa: This letter sets forth the substance of the transition and separation agreement (the ?Agreement?) that ChromaDex Corporation (the ?Company?) is offering to you to aid in your employment transition. 1.Separation. Your last day of work with the Company and |
|
| May 12, 2022 |
Exhibit 10.2 AMENDMENT TO THE CHROMADEX, INC. - DARTMOUTH RESTATED AND AMENDED EXCLUSIVE LICENSE AGREEMENT This Amendment (this ?Amendment?), dated as of this 29th day of December, 2020 with effect from and after March 13, 2017 (the ?Amendment Effective Date?), to the ChromaDex, Inc. - Dartmouth Restated and Amended Exclusive License Agreement, dated September 2019 (?License Agreement?), is made b |
|
| May 12, 2022 |
ChromaDex Corporation Reports First Quarter 2022 Financial Results Total net sales of $17. |
|
| May 12, 2022 |
Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. September 3, 2019 Ms. Nila Bhakuni Director Technology Transfer Office Dartmouth College 11 Rope Ferry Road, HB 6210 Hanover, New Hampshire 03755 Chromadex - Dartmouth Side Letter Agreement: De |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission File |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 Commission File Number: 001-37752 CHROMADEX CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 26-2940963 (State or other jurisdiction of incorporation or or |
|
| May 12, 2022 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SECOND AMENDMENT TO THE CHROMADEX, INC. - DARTMOUTH RESTATED AND AMENDED EXCLUSIVE LICENSE AGREEMENT This Amendment (this ?Amendment?), effective as of this 1st day of January, 202 |
|
| May 12, 2022 |
Exhibit 10.6 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. JOINT OWNERSHIP MANAGEMENT AGREEMENT This Joint Ownership Management Agreement (?Agreement?) is made effective the 09 October 2015 (?Effective Date?) by and between (1) THE QUEEN?S |
|
| May 12, 2022 |
Exhibit 10.5 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT TO / JOINT OWNERSHIP MANAGEMENT AGREEMENT THIS AMENDMENT is entered into this 10th day of March 2022 (the ?Effective Date of the Amendment?), by and between ChromaDex, In |
|
| May 12, 2022 |
Exhibit 10.4 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. CHROMADEX, INC. - DARTMOUTH RESTATED AND AMENDED EXCLUSIVE LICENSE AGREEMENT This Agreement, effective the 13th day of March 2017 between TRUSTEES OF DARTMOUTH COLLEGE, a non-profi |
|
| May 12, 2022 |
ChromaDex Earnings Conference Call First Quarter 2022 Rob Fried Chief Executive Officer Frank Jaksch Co-Founder / Executive Chairman Kevin Farr Chief Financial Officer Nasdaq: CDXC | May 2022 SAFE HARBOR STATEMENT This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain ?forward-looking statements? within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. |
|
| April 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2022 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission Fi |
|
| April 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2022 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission Fi |
|
| April 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2022 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2022 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 23, 2022 |
Investor Presentation Rob Fried Chief Executive Officer Kevin Farr Chief Financial Officer Nasdaq: CDXC | March 2022 ChromaDex Investment Highlights ? Leader in the rapidly growing NAD+ market ? Proven and proprietary NAD+ boosting supplement supported by 20 clinical trials ? Strong revenue growth (34% CAGR(1)) driven by e-commerce and strong gross margins (61. |
|
| March 23, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2022 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 14, 2022 |
Amended and Restated Bylaws of the Registrant EX-3.3 2 chromadex-amendedandrestat.htm EX-3.3 AMENDED AND RESTATD BYLAWS OF CHROMADEX CORPORATION (hereinafter called the “Corporation”) ARTICLE I. OFFICES Section 1.Registered Office. The registered office of the Corporation in the State of Delaware shall be in the Corporation Trust Center, 1209 Orange Street, in the ‘City of Wilmington, County of New Castle, Delaware, 19801 and the name of the |
|
| March 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission file number 001-37752 CHROMADEX CORPORATION ( |
|
| March 14, 2022 |
Lease, dated November 24, 2021, by and between Flight Phase I Owner, LLC and ChromaDex, Inc. EX-10.59 5 leasedatednovember242021by.htm EX-10.59 OFFICE LEASE AGREEMENT CALIFORNIA FLIGHT AT TUSTIN LEGACY TUSTIN, CA THIS OFFICE LEASE AGREEMENT (the "Lease") is made and entered into as of the 24th day of November, 2021, by and between FLIGHT PHASE I OWNER, LLC, a Delaware limited liability company ("Landlord") and CHROMADEX CORPORATION, a Delaware corporation ("Tenant"). Pursuant to the terms |
|
| March 14, 2022 |
EX-21.1 6 subsidiariesofchromadexcor.htm EX-21.1 SUBSIDIARIES OF THE REGISTRANT (As of December 31, 2021) Entity Name President Company / Owner Jurisdiction of Formation ChromaDex, Inc. ChromaDex Corporation California ChromaDex International, Inc. ChromaDex Corporation Cayman Islands ChromaDex Analytics, Inc. ChromaDex, Inc. Nevada ChromaDex Europa B.V. ChromaDex, Inc. Netherlands Chromadex Sağlı |
|
| March 14, 2022 |
Supply Agreement, dated December 19, 2018, by and between ChromaDex, Inc. and Nestec Ltd. * CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| March 14, 2022 |
SECOND MODIFICATION TO BUSINESS FINANCING AGREEMENT This Second Modification to Business Financing Agreement (this ?Amendment?) is entered into as of November 10, 2021, by and among WESTERN ALLIANCE BANK, an Arizona corporation (?Lender?), CHROMADEX CORPORATION, a Delaware corporation, and CHROMADEX, INC. |
|
| March 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2022 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 9, 2022 |
EX-99.1 2 exhibit991-pressreleasexq4.htm EX-99.1 ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2021 Results Total net sales of $67.4 million for the full year, up 14% from the prior year, with $56.7 million from Tru Niagen® and gross margin of 61.5%. Total net sales of $17.8 million for the three months ended December 31, 2021, up 15% from the prior year quarter. LOS ANGELES, CA - M |
|
| March 9, 2022 |
1 ChromaDex Earnings Conference Call Fourth Quarter 2021 Rob Fried Chief Executive Officer Kevin Farr Chief Financial Officer Andrew Shao SVP Scientific & Regulatory Affairs Nasdaq: CDXC | March 9, 2022 2SAFE HARBOR STATEMENT This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain ?forward- looking statements? within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. |
|
| February 11, 2022 |
CDXC / Chromadex Corp / Li Ka Shing (Global) Foundation - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* ChromaDex Corporation (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 171077407 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| February 11, 2022 |
EX-99.1 2 d187133dex991.htm EX-99.1 EXHIBIT 99.1 Joint Filing Agreement The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The unders |
|
| December 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2021 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission |
|
| December 15, 2021 |
THIRD MODIFICATION TO BUSINESS FINANCING AGREEMENT This Third Modification to Business Financing Agreement (this ?Amendment?) is entered into as of December 1, 2021, by and among WESTERN ALLIANCE BANK, an Arizona corporation (?Lender?), CHROMADEX CORPORATION, a Delaware corporation, CHROMADEX, INC. |
|
| December 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2021 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission |
|
| December 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2021 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission |
|
| November 3, 2021 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [?***?], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT CHROMADEX CORPORATION TREATS AS PRIVATE OR CONFIDENTIAL SEVENTH AMENDMENT Manufacturing and Supply Agreement between W. |
|
| November 3, 2021 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [?***?], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT CHROMADEX CORPORATION TREATS AS PRIVATE OR CONFIDENTIAL EXCLUSIVE LICENSE AGREEMENT between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA and CHROMADEX INC. |
|
| November 3, 2021 |
ChromaDex Corporation Reports Third Quarter 2021 Financial Results Total company net sales of $17. |
|
| November 3, 2021 |
EX-99.2 3 cdxcearningspresentation.htm EX-99.2 1 ChromaDex Earnings Conference Call Third Quarter 2021 Rob Fried Chief Executive Officer Frank Jaksch Co-Founder / Executive Chairman Kevin Farr Chief Financial Officer Fadi Karam Chief Marketing Officer Nasdaq: CDXC | November 3, 2021 2SAFE HARBOR STATEMENT This presentation and other written or oral statements made from time to time by representati |
|
| November 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 Commission File Number: 001-37752 CHROMADEX CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 26-2940963 (State or other jurisdiction of incorporation o |
|
| November 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2021 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission |
|
| October 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2021 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission |
|
| September 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2021 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commissio |
|
| September 21, 2021 |
CDXC / Chromadex Corp / Chau Hoi Shuen Solina Holly - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) INFORMATION INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 12)* CHROMADEX CORPORATION (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 171077407 (CUSIP Number) Pioneer Step Holdings Lim |
|
| September 21, 2021 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(f) under the Securities and Exchange Act of 1934, the persons or entities named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Shares of the Issuer and further agree that this joint filing agreement be included as an exhibit to this Schedule |
|
| September 20, 2021 |
CDXC / Chromadex Corp / Chau Hoi Shuen Solina Holly - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) INFORMATION INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 11)* CHROMADEX CORPORATION (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 171077407 (CUSIP Number) Pioneer Step Holdings Limited Dvor |
|
| September 20, 2021 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(f) under the Securities and Exchange Act of 1934, the persons or entities named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Shares of the Issuer and further agree that this joint filing agreement be included as an exhibit to this Schedule |
|
| September 17, 2021 |
CDXC / Chromadex Corp / Chau Hoi Shuen Solina Holly - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) INFORMATION INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 10)* CHROMADEX CORPORATION (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 171077407 (CUSIP Number) Pioneer Step Holdings Limited Dvor |
|
| September 17, 2021 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(f) under the Securities and Exchange Act of 1934, the persons or entities named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Shares of the Issuer and further agree that this joint filing agreement be included as an exhibit to this Schedule |
|
| September 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 14, 2021 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commissio |
|
| August 3, 2021 |
License Agreement, dated July 5, 2011 between ChromaDex, Inc. and Cornell University CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT CHROMADEX CORPORATION TREATS AS PRIVATE OR CONFIDENTIAL Exhibit 10. |
|
| August 3, 2021 |
ChromaDex Corporation Reports Second Quarter 2021 Financial Results Tru Niagen? net sales of $15. |
|
| August 3, 2021 |
EXHIBIT 10.1 FIFTH AMENDMENT TO LEASE This FIFTH AMENDMENT TO LEASE (this "Fifth Amendment") is made and entered into as of May 21, 2021, by and between 10900 WILSHIRE, L.L.C., a Delaware limited liability company ("Landlord"), and CHROMADEX, INC., a California corporation ("Tenant"). R E C I T A L S : A.Landlord and Tenant are parties to that certain Lease, dated July 6, 2017 (the "Original Lease |
|
| August 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 Commission File Number: 001-37752 CHROMADEX CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 26-2940963 (State or other jurisdiction of incorporation or org |
|
| August 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2021 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 3, 2021 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [?***?], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT CHROMADEX CORPORATION TREATS AS PRIVATE OR CONFIDENTIAL SEVENTH AMENDMENT Manufacturing and Supply Agreement between W. |
|
| August 3, 2021 |
1 ChromaDex Earnings Conference Call Second Quarter 2021 Rob Fried Chief Executive Officer Frank Jaksch Co-Founder / Executive Chairman Kevin Farr Chief Financial Officer Nasdaq: CDXC | August 3, 2021 2SAFE HARBOR STATEMENT This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain ?forward-looking statements? within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. |
|
| June 22, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2021 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 6, 2021 |
Consultant Agreement, dated March 15, 2021, by and between Mark Friedman and the Registrant❖ EXHIBIT 10.3 CONSULTANT AGREEMENT This Agreement is made as of this March 15, 2021 (?Effective Date?) by and between ChromaDex, Inc., with a notice address of 10900 Wilshire Blvd., Suite 600, Los Angeles, California 90024, (?ChromaDex?), and Mark Friedman, an individual, with a notice address of 5432 Hermitage Ave. #302, Valley Village, CA 90607 (?Consultant?). ChromaDex and Consultant are sometim |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 6, 2021 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission File |
|
| May 6, 2021 |
EX-10.4 4 cdxcex104.htm CONSENT TO BUSINESS FINANCING AGREEMENT EXHIBIT 10.4 CONSENT TO BUSINESS FINANCING AGREEMENT This Consent to Business Financing Agreement (this “Amendment”) is entered into as of January 14, 2021, by and among WESTERN ALLIANCE BANK, an Arizona corporation (“Lender”), CHROMADEX CORPORATION, a Delaware corporation (“Chromadex Corp”), CHROMADEX, INC., a California corporation |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 Commission File Number: 001-37752 CHROMADEX CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 26-2940963 (State or other jurisdiction of incorporation or or |
|
| May 6, 2021 |
EXHIBIT 10.2 CHROMADEX CORPORATION EXECUTIVE EMPLOYMENT AGREEMENT for Lisa Hatton Harrington This Executive Employment Agreement (this ?Agreement?) is entered into as of November 13, 2020 (the ?Effective Date?), by and between Lisa Hatton Harrington (?Executive?) and ChromaDex Corporation, a Delaware corporation (the ?Company?). 1. Employment by the Company. 1.1 Position. Commencing on December 3, |
|
| May 6, 2021 |
Exhibit 99.2 |
|
| May 6, 2021 |
Exhibit 99.1 ChromaDex Corporation Reports First Quarter 2021 Financial Results Tru Niagen? Revenue for the Three-Month Period Ended March 31, 2021 Totals $12.4 Million, up 12% Year-over-Year, with Total Company Revenue of $14.7 Million and Gross Margin of 62.9%. LOS ANGELES, May 6, 2021 (GLOBE NEWSWIRE) - ChromaDex Corp. (NASDAQ:CDXC) today reported first quarter 2021 financial results. First Qua |
|
| April 22, 2021 |
PROSPECTUS 3,846,153 Shares Common Stock Offered by the Selling Stockholder Filed pursuant to Rule 424(b)(3) Registration No. 333-254624 PROSPECTUS 3,846,153 Shares Common Stock Offered by the Selling Stockholder This prospectus relates to the offer and resale by a selling stockholder from time to time of up to 3,846,153 shares of our common stock, par value $0.001 per share (“Common Stock”). The selling stockholder may sell the shares of Common Stock described in this pr |
|
| April 21, 2021 |
- DEFINITIVE ADDITIONAL MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 21, 2021 |
ChromaDex Corporation 10900 Wilshire Blvd., Suite 600 Los Angeles, California 90024 (310) 388-6706 ChromaDex Corporation 10900 Wilshire Blvd., Suite 600 Los Angeles, California 90024 (310) 388-6706 April 21, 2021 Via Edgar United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Margaret Schwartz Re: ChromaDex Corporation Registration Statement on Form S-3 Filed: March 23, 2021 File No. 333-254624 Acceleration Request Reque |
|
| April 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| March 23, 2021 |
As filed with the United States Securities and Exchange Commission on March 23, 2021 Registration No. |
|
| March 12, 2021 |
Subsidiaries of ChromaDex Corporationv EXHIBIT 21.1 ChromaDex Corporation Corporate Organization Chart at December 31, 2020 (1) Healthspan Research, LLC was subsequently dissolved in January 2021. |
|
| March 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 001-37752 CHROMADEX CORPORATION (E |
|
| March 12, 2021 |
EXHIBIT 10.44 FIRST MODIFICATION TO BUSINESS FINANCING AGREEMENT This First Modification to Business Financing Agreement (this ?Amendment?) is entered into as of October 7, 2020, but is effective as of September 1, 2020, by and among WESTERN ALLIANCE BANK, an Arizona corporation (?Lender?), CHROMADEX CORPORATION, a Delaware corporation, CHROMADEX, INC., a California corporation, CHROMADEX ANALYTIC |
|
| March 12, 2021 |
EXHIBIT 10.52 CHROMADEX CORPORATION EXECUTIVE EMPLOYMENT AGREEMENT for MEGAN JORDAN This Executive Employment Agreement (this ?Agreement?) is entered into as of July 23, 2019 (the ?Effective Date?), by and between Megan Jordan (?Executive?) and ChromaDex Corporation, a Delaware corporation (the ?Company?). 1. Employment by the Company. 1.1 Position. Commencing on August 6, 2019, Executive shall se |
|
| March 10, 2021 |
EX-99 3 cdxcex992.htm 99.2 Exhibit 99.2 |
|
| March 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 10, 2021 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 10, 2021 |
Exhibit 99.1 ChromaDex Corporation Reports 2020 Financial Results Revenue for the Three-Month Period Ended December 31, 2020 Totals $15.4 Million, up 18% Year-over-Year, with Gross Margin of 61.0%, and Lower Operating Expenses. Full Year Revenue of $59.3 Million, with $47.1 Million from Tru Niagen?. LOS ANGELES, March 10, 2021 (GLOBE NEWSWIRE) - ChromaDex Corp. (NASDAQ:CDXC) today reported fourth |
|
| March 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D/A (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 Chromadex Corporation (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 171077407 (CUSIP Number) Ph |
|
| February 25, 2021 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 23, 2021 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission |
|
| February 22, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 20, 2021 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission |
|
| February 22, 2021 |
Exhibit 99.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 20, 2021, between ChromaDex Corporation, a Delaware corporation (the “Company”), and the purchaser identified on the signature pages hereto (including its successors and assigns, the “Purchaser”). WHEREAS, subject to the terms and conditions set forth in this Agreement, the Comp |
|
| February 22, 2021 |
Exhibit 99.2 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (the “Agreement”) is made as of February 20, 2021 by and between ChromaDex Corporation, a corporation organized and existing under the laws of the State of Delaware (the “Company”), and the purchaser signatory hereto (the “Purchaser”). RECITALS WHEREAS, the Company and the Purchaser are parties to a Securities Purchase A |
